Shares of Hims & Hers Health fell 4% to $25.79 on a day the company unveiled a splashy new product, raising a pointed question: is the telehealth firm's AI ambition running ahead of investor patience? Hims & Hers Bets Big on AI Healthcare — So Why Is Wall Street Walking Away Four Days Before Earnings?

Shares of Hims & Hers Health slid 4% to $25.79 on a day meant to showcase the company's AI-powered future, exposing a growing gap between management's vision and Wall Street's willingness to pay for it. The company is set to report first-quarter 2026 results on May 11 , making the timing of today's selloff particularly telling.

  • The New Product Sounds Impressive, But Revenue Impact Is a Question Mark. Hims unveiled its AI-powered care agent designed to deliver proactive health monitoring — essentially a digital assistant that nudges users about their lab results and wellness goals. The company promises "smarter intakes, improved biomarker insights," and personalized care tools it calls a "revolution in accessible, affordable concierge care," with AI powering precision treatments "previously only available to very few." The problem: none of this has a price tag or subscriber conversion target attached yet. Until the company shows how AI tools translate into paying customers, the announcement reads as marketing, not a catalyst.

  • Earnings Estimates Have Collapsed Ahead of Sunday's Report. Wall Street expects a "sharp earnings deceleration," with consensus earnings per share of just $0.03 on revenue of $616.9 million — and the range spans from a loss of $0.04 to a gain of $0.15, reflecting huge uncertainty.

Three months ago, analysts modeled EPS of $0.14 — a 78.6% cut to current expectations.

Last year, the company earned $0.20 per share in Q1, meaning consensus implies an 85% year-over-year profit decline even as revenue grows a modest 5.3%. That margin squeeze is what investors are really trading today.

  • The Stock Is Cheap for a Reason — And Investigations Don't Help. HIMS trades at a forward price-to-sales ratio (a measure comparing stock price to expected revenue) of just 1.9x, well below the industry average of 3.7x.

Shares have lost 44.8% over the past year, underperforming even the struggling telehealth sector.

Adding to the overhang, law firms have recently initiated fraud investigations into the company's officers and directors , clouding an already cautious sentiment.

  • AI Spending Could Widen the Profit Gap Before Closing It. Analysts warn that "heavier AI and lab investments could pressure margins."

The Zacks consensus projects only a 15.1% EPS improvement for full-year 2026 and carries a Hold rating — hardly a ringing endorsement of a transformative AI pivot. Fourteen analysts maintain a Buy consensus with a $32.57 average price target , suggesting upside if execution follows, but Sunday's earnings call will be the first real test of whether AI ambitions are costing more than they're creating.